Molecular Genetic Tumour Panel (dog)

LABOKLIN Service ID: 1258


Panel for a more precise characterisation of malignant tumours in dogs in selected cases:

Therapeutic indications

  • No known or conventional treatment concepts
  • (Treatment-resistant) recurrence
    • Genome-based individualised treatment may potentially offer a new therapeutic option (please pay attention to the European Cascade Rule, if applicable).

    Diagnostic indication
  • A reliable cytological or (immuno)histological diagnosis was not possible.
  • The molecular genetic signature can help to further refine the diagnosis (e.g. histiocytic neoplasia versus inflammation), and possibly a therapeutic option may also be identified.

    • Material

  • 15 smears rich in tumour cells (not covered)
  • Biopsies > 0.5 cm (formalin-fixed)
  • Tumour resections (formalin-fixed)
  • Paraffin blocks with sufficient tumour material (paraffin rolls or decalcified tissue are not suitable)

    • Parameter

    Analysis of approximately 20,000 genes for mutations

    Method

    Next Generation Sequencing (NGS) (VetOmics, Canine CGP®)

    Species list

    Dog

    Duration

    Approx. 3 weeks

    Remark

  • Summary of the molecular genetic results
  • Explanations and literature references on the biomarkers found
  • Specification of the tumour mutation burden to predict response to checkpoint inhibitors (e.g. PD-1, PDL-1 inhibitors, APAVAC)
  • Suitable drugs for individualised tumour treatment are suggested, along with dosages and information on the level of evidence.
  • If required, further advice on the treatment options identified is provided directly by the oncologists in the USA via email (in English).

    • Limitations
  • A sufficient number of tumour cells and DNA quality are required
  • It is not always possible to isolate DNA in sufficient quantity and quality
  • It is not always possible to find mutations that open up therapeutic options.
  • The availability and costs of medication may vary between countries.
  • The drugs may not be approved for dogs in all countries.
  • The efficacy of these medications in dogs is supported by varying degrees of evidence
  • Data on effectiveness and side effects in the respective canine tumours is often incomplete.

    • The decision and responsibility for using the medication listed in the findings lies with the veterinarian in charge! It is recommended to consult a specialised oncologist in such cases.